Verge Genomics
We use human data and AI to develop better drugs faster.
Based based in San Francisco, CA, USA, Verge Genomics works in healthcare.
Profile
Verge uses artificial intelligence and human data to develop better drugs faster. Verge has an end-to-end technology-driven drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets from human tissue. Verge uses machine learning to mine this data and develops these insights into new drugs using it’s human-centric biology and chemistry platforms.
Its activity falls under healthcare; the profile below is assembled from public directory data.
The company is recorded as being based in San Francisco, CA, USA.
The company is listed at the Summer 2015 stage of development.
The company reports a headcount in the 50 range.
Directory analysis
Verge Genomics develops an end‑to‑end drug discovery platform that leverages artificial intelligence and a large proprietary patient genomics dataset. The company combines machine‑learning‑derived insights with human‑centric biology and chemistry tools to accelerate the creation of new therapeutics. It positions itself as a technology‑driven alternative to traditional, slower drug development pipelines.
Positioning: Verge Genomics operates in the highly competitive biotech space, focusing on AI‑driven discovery to shorten timelines and reduce costs. Its proprietary data assets and integrated platform may give it a unique niche, though success will depend on translating insights into marketable drugs.
Note: Founded in 2015, Verge Genomics is headquartered in San Francisco, CA.
Auto-generated directory analysis from public data · updated 2026-10-06 02:16:06. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | San Francisco, CA, USA |
| Country | USA |
| Employees | 50 |
| Stage | Summer 2015 |
Website: vergegenomics.com
Browse related
Create a free account